Peloton Interactive, Inc. PTON is likely to witness sequential improvement in the bottom line, when the company reports fourth-quarter fiscal 2020 results. In the last reported quarter, the company’s earnings missed the Zacks Consensus Estimate by 11.1%.
Factors to Note
Increase in demand for the company’s Connected Fitness Products and Subscription services might get reflected in the fiscal fourth-quarter top line. The company’s in-house exercise equipment like treadmills and stationary bikes are likely to have been in demand among fitness enthusiasts amid the coronavirus pandemic.
Moreover, increase in digital subscribers, attributable to improvements in its fitness content and features made available on its digital app, may have positively impacted the company’s to-be-reported quarter’s performance. Notably, the company recently launched an app on Apple TV and Amazon Fire TV.
What Our Model Says
Our proven model predicts an earnings beat for Peloton this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the odds of an earnings beat.
Earnings ESP: Peloton has an Earnings ESP of +7.63%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Peloton carries a Zacks Rank #2.
Other Stock With Favorable Combinations
Here are some other stocks from the Zacks Consumer Discretionary space that investors may consider, as our model shows that these too have the right combination of elements to deliver an earnings beat this time around.
Callaway Golf Company ELY has an Earnings ESP of +222.5% and a Zacks Rank #3, at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Acushnet Holdings Corp. (GOLF): Free Stock Analysis Report
Vista Outdoor Inc. (VSTO): Free Stock Analysis Report
Callaway Golf Company (ELY): Free Stock Analysis Report
Peloton Interactive, Inc. (PTON): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.